NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) on Monday unveiled a leadership succession plan, with Chief Financial Officer Ron McClurg set to retire on June 30, 2026, after more than five years with the company. McClurg will remain as a Senior Advisor through December 31, 2026, to ensure a smooth transition. Chris Volker, currently serving as Chief Operating Officer, will assume the permanent CFO role, while newly appointed Chief Business Officer David Wambeke will take on many of Volker's prior responsibilities.
The transition comes as NeuroOne continues to commercialize its minimally invasive electrode technology platform, which includes four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for the brain, and OneRF Trigeminal Nerve Ablation System. The company is also advancing research and development in drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. CEO Dave Rosa expressed gratitude for McClurg's contributions, stating, "Ron's retirement marks the culmination of a long and successful career, and we are grateful for his leadership, stewardship, and commitment to NeuroOne."
Rosa highlighted Volker's deep medtech experience, noting that Volker brings "more than 25 years of progressive operational and financial leadership experience, including extensive experience in the medical device industry." Volker, a CFA charterholder with an MBA from The Wharton School of the University of Pennsylvania, previously held senior roles at Abbott, Cardiovascular Systems Inc. (CSI), and St. Jude Medical. At CSI, he served as Vice President & General Manager of International, overseeing international P&L and commercial expansion. Earlier in his career, he worked in healthcare and technology investment banking at Dain Rauscher, gaining expertise in financial analysis, mergers and acquisitions, and strategic planning.
McClurg reflected on his tenure, saying, "It has been a privilege to serve as NeuroOne's Chief Financial Officer for over five years and to work alongside such a talented team. I am proud of this team and the benefits our products are providing for patients." He affirmed his commitment to supporting the transition. The leadership changes are effective amid NeuroOne's strategic growth. The company markets a high-definition electrode technology platform designed to reduce hospitalizations and surgical procedures while improving outcomes for patients with neurological disorders. NeuroOne's products offer both diagnostic and therapeutic functions, and the company continues to explore new applications.
Volker expressed enthusiasm for his new role, stating, "I am honored to take on the role of Chief Financial Officer and appreciate the confidence the Board and the management team have placed in me. NeuroOne has built strong momentum, both in advancing our product pipeline and commercially." He emphasized working with the team and McClurg during the transition to support the company's strategic and financial objectives. For more information about NeuroOne and its technologies, visit nmtc1.com.
This leadership transition is significant for HR vendors and the broader talent management industry, as it underscores the importance of succession planning in medtech firms navigating commercialization phases. The appointment of an internal candidate with both operational and financial expertise reflects a trend toward cross-functional leadership, which may influence how vendors design executive development and retention programs. Additionally, the phased retirement and advisory role model could offer a template for knowledge transfer, impacting how HR technology solutions address workforce planning and leadership continuity.
